CoVPN Cross-Protocol Analyses
CoVPN Cross-Protocol Analyses
批准号:
10322571
负责人:
Peter B. Gilbert
金额:
$58.96万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-02 至 2022-03-31
关键词:
2019-nCoVAddressAntibodiesBiometryCOVID-19COVID-19 Prevention NetworkCOVID-19 outbreakCOVID-19 pandemicCOVID-19 vaccineClinicalClinical Trials NetworkDiseaseEnrollmentHIV Vaccine Trials NetworkHealthImmuneImmune responseImmunityIncidenceIndividualInfectionLaboratoriesLeadLeadershipMediator of activation proteinMethodsModelingMonitorParticipantPeriodicityPhasePopulationProtocols documentationReportingReproducibilityRiskSARS-CoV-2 infectionSafetySignal TransductionSiteStandardizationStatistical MethodsTechniquesUnited States National Institutes of HealthVaccinationVaccinesWorkbasecohortcomputer codedata managementdesignefficacy trialepidemiological modelexperienceimmunogenicityimprovedinnovationintervention effectpathogenrecruitresponsetoolvaccine efficacyvaccine evaluationvaccine safetyvaccine trial
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Abstract
This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines
Statistical and Data Management Center (SDMC) for implementation of cross-protocol work in support of
COVID-19 phase 3 efficacy trials.
With the global COVID-19 pandemic, we recognize a significant need for vaccines that modify COVID-19 in
SARS-CoV-2 infected individuals. Addressing this gap, the HVTN SDMC has joined 4 other National Institute
of Health (NIH) clinical trial networks to form the CoVPN, an enhanced network dedicated to developing
globally effective vaccines for SARS-CoV-2.
The innovation of the CoVPN SDMC and advantages to this work include the collective experience of our
group- leader in statistical methods in vaccine evaluation, especially immune correlates assessment, and the
long-standing relationships we have with the clinical and lab groups in the CoVPN lead
Adapting and leveraging statistical methods for evaluating vaccines against other pathogens to SARS-CoV-2.
E.g. causal inference methods for evaluating multiple types of formally defined correlates of protection
including correlates of vaccine efficacy, mediators of vaccine efficacy, and stochastic-intervention effects on
vaccine efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CoVPN Cross-Protocol Analyses
-
批准号:10570780
-
项目类别:
-
资助金额:$133.49万
-
财政年份:2022
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection
-
批准号:10581432
-
项目类别:
-
资助金额:$81.85万
-
财政年份:2022
-
负责人:Peter B. Gilbert
-
依托单位:
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals
-
批准号:10570787
-
项目类别:
-
资助金额:$101.18万
-
财政年份:2022
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine
-
批准号:10375264
-
项目类别:
-
资助金额:$203.47万
-
财政年份:2021
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC
-
批准号:10319288
-
项目类别:
-
资助金额:$67.35万
-
财政年份:2021
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older SDMC
-
批准号:10320660
-
项目类别:
-
资助金额:$1832.23万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa
-
批准号:10609096
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN Cross-Protocol Analyses
-
批准号:10247368
-
项目类别:
-
资助金额:$136.73万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine SDMC
-
批准号:10217912
-
项目类别:
-
资助金额:$141.43万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals
-
批准号:10166307
-
项目类别:
-
资助金额:$40.16万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa
-
批准号:10378762
-
项目类别:
-
资助金额:$33.64万
-
财政年份:2020
-
负责人:Peter B. Gilbert
-
依托单位:
Statistical Methods in HIV Vaccine Efficacy Trials
-
批准号:9251714
-
项目类别:
-
资助金额:$36.88万
-
财政年份:2015
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3004 A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a SARS-CoV-2 Spike Protein Nanoparticle Vaccine in Adults
-
批准号:10581423
-
项目类别:
-
资助金额:$23.49万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN Cross-Protocol Analyses
-
批准号:10581848
-
项目类别:
-
资助金额:$184.68万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
-
批准号:10582009
-
项目类别:
-
资助金额:$1484.46万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3002 - A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study in Adults to Determine the safety, Efficacy, and Immunogenicity of AZD1222 for Prevention of Covid-19
-
批准号:10581359
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection SDMC
-
批准号:10570788
-
项目类别:
-
资助金额:$47.79万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
SDMC: HIV Vaccine Trials Network
-
批准号:8782602
-
项目类别:
-
资助金额:$1324.18万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals
-
批准号:10582056
-
项目类别:
-
资助金额:$29.37万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
CoVPN 3006 - A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine
-
批准号:10581427
-
项目类别:
-
资助金额:$45.36万
-
财政年份:2006
-
负责人:Peter B. Gilbert
-
依托单位:
海外基金